Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
DiNAK Therapeutics
San Diego, California, United Statesdinaktx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
DiNAK Therapeutics is a biotechnology company specializing in the development of precision oncology therapies targeting the DNA damage response (DDR) pathway. The company's primary focus is on creating highly selective small molecule inhibitors that address the limitations of first-generation DDR agents, particularly regarding off-target toxicity. Its lead candidate, DNK-01, is a selective WEE1 inhibitor currently in IND-enabling studies for the treatment of various solid tumors. DiNAK was founded by the former executive team of Zentalis Pharmaceuticals, bringing significant expertise in medicinal chemistry and oncology drug development. The company aims to provide new treatment options for patients with cancers harboring specific genetic vulnerabilities.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on DiNAK Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DiNAK Therapeutics.